Clinical Trial Search

Primary: Change From Baseline in PANSS Total Score at Week 6 — -19.3; -16.9; -19.6 score on a scale — p=0.886

Primary: Proportion of Subjects With ≥1-point Improvement on Investigator Global Aesthetic Improvement Scale (I-GAIS) at Day 90 (Buttocks) — 3; 2 Participants

Primary: Change in Physical Function (Part 1) — -15.0; -12.6 Seconds — p=0.35

Primary: To Validate the Haptic Module and Insole Device System and Evaluate Its Efficacy With an In-community Clinical Trial. — 4.40; 5.69 seconds

Primary: Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A Only) — 0; 0; 0; 1 Participants

Primary: Change in Self-reported Nutrition Practices — 3.20; 3.06; 3.25; 3.20 units on a scale — p=0.25

Primary: Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS — 35 injections

Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2

Primary: Primary Patency of AVF — 88 Participants

Primary: Number of Participants With Incident Tuberculosis — 20; 34 Participants

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970 — 380; 1380 nanogram*hour per milliliter…

Primary: Number of Participants Who Experienced Psychological IPV — 62; 60; 42; 47 Participants

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970 — 130; 132; 209; 611 nanogram *hour per…

Primary: Change in Heart Rate — -2.40; -0.94 beat per minute

Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion